Dipal Doshi - 16 May 2024 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Signature
/s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol
TRDA
Transactions as of
16 May 2024
Net transactions value
-$45,129
Form type
4
Filing time
20 May 2024, 17:21:58 UTC
Previous filing
05 Mar 2024
Next filing
14 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Sale $27,000 -1,800 -0.53% $15.00 338,575 16 May 2024 Direct F1
transaction TRDA Common Stock Sale $18,129 -1,200 -0.35% $15.11 337,375 17 May 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023.